ChengDa Pharmaceuticals Co., Ltd.

XSEC:301201 Stock Report

Market Cap: CN¥3.3b

ChengDa Pharmaceuticals Past Earnings Performance

Past criteria checks 3/6

ChengDa Pharmaceuticals's earnings have been declining at an average annual rate of -1.8%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 2% per year. ChengDa Pharmaceuticals's return on equity is 3.9%, and it has net margins of 21.1%.

Key information

-1.8%

Earnings growth rate

-11.0%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-2.0%
Return on equity3.9%
Net Margin21.1%
Next Earnings Update29 Oct 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How ChengDa Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XSEC:301201 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24412879437
31 Mar 24413908732
31 Dec 23414918727
30 Sep 23366767821
30 Jun 23361718120
31 Mar 234051008519
01 Jan 234111068919
30 Sep 224321229020
30 Jun 224381158319
31 Mar 224361067618
01 Jan 224161006817
30 Sep 2139612610331
31 Dec 203731215519
31 Dec 19294545212
31 Dec 182037469

Quality Earnings: 301201 has a high level of non-cash earnings.

Growing Profit Margin: 301201's current net profit margins (21.1%) are higher than last year (19.6%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 301201's earnings have declined by 1.8% per year over the past 5 years.

Accelerating Growth: 301201's earnings growth over the past year (22.7%) exceeds its 5-year average (-1.8% per year).

Earnings vs Industry: 301201 earnings growth over the past year (22.7%) exceeded the Pharmaceuticals industry -0.6%.


Return on Equity

High ROE: 301201's Return on Equity (3.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies